Cloning the hepatitis E virus may lead to creation of a vaccine
Scientists at the All India Institute of Medical Sciences (aiims), New Delhi, have developed the first genetically-engineered clone of the hepatitis E virus.
"Such an achievement will not only help in the development of a vaccine but also make it possible to identify a drug that can inhibit this virus," says S K Panda, professor of pathology at AIIMS. The institute has already applied for a patent on the viral clone and the cloning process.
Hepatitis E, as in the case of other hepatitis virus strains, is spread through contaminated drinking water. It targets the liver, where it multiplies and destroys cells. Hepatitis viruses have caused several epidemics in India. They mostly affect adults between 20 years and 40 years. Around five million Indians are affected by hepatitis each year and about 500,000 die each year.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
.png)
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.